Linda Shu
Coverage of Linda Shu in the Nexus archive.
- Wall Street funds back China’s WuXi AppTec as weight-loss drug orders soar
US global asset managers, including BlackRock, have increased investments in WuXi AppTec, a Chinese pharmaceutical contractor, anticipating higher earnings from a surge in weight-loss drug manufacturing orders. HSBC's Linda Shu noted growing investor interest in China's contract development and manufacturing organisation and biotechnology sectors.
- Wall Street funds back China’s WuXi AppTec as weight-loss drug orders soar
US global asset managers, including BlackRock, have increased stakes in China's WuXi AppTec, anticipating higher earnings from a surge in weight-loss drug manufacturing orders. Investors show growing interest in China’s contract development and manufacturing organizations and biotechnology sectors, as noted by HSBC's Linda Shu.
- China AI drug-design deals swell as US scrutiny mounts
China's AI-driven drug-design firms are expanding globally through cross-border dealmaking, with out-licensing deals to major pharmaceutical companies reaching $75 billion in the first five months of 2026, up from zero before 2020. This growth occurs despite increasing US scrutiny of Chinese biotech firms.
- China AI drug-design deals swell as US scrutiny mounts
Chinese AI-driven drug-design firms are securing global deals despite US scrutiny, with out-licensing deals reaching $75 billion in the first five months of 2026, up from zero before 2020.